Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) is a dermatology therapeutics company whose news flow centers on clinical milestones, regulatory developments, commercial progress and financing activities related to its skin disease portfolio. The company’s updates frequently highlight YCANTH® (VP-102), a cantharidin-based, healthcare professional-administered treatment approved by the FDA for molluscum contagiosum, and its expansion into new indications and geographies.
Investors following VRCA news can expect regular announcements on YCANTH’s commercial performance in the United States, including dispensed applicator trends and net product revenue, as well as collaboration and milestone revenue from Torii Pharmaceutical Co. Ltd. in Japan. News items also cover regulatory interactions, such as positive feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use supporting a Marketing Authorization Application for YCANTH in the European Union, and approval of TO-208 (YCANTH) for molluscum contagiosum in Japan.
Another major theme in Verrica’s news is pipeline progress. The company reports data from clinical trials of YCANTH in common warts, including Phase 2 results and the initiation of a global Phase 3 program, and provides detailed updates on VP-315, its oncolytic peptide immunotherapy for non-melanoma skin cancers such as basal cell carcinoma. Presentations at scientific meetings, exploratory immunologic analyses and alignment with the U.S. Food and Drug Administration on Phase 3 study designs are common subjects of these releases.
VRCA news also includes corporate and capital markets developments, such as private placement financings, reverse stock split actions, Nasdaq listing compliance updates and conference presentations at investor events. For readers interested in dermatology therapeutics, viral skin infections and non-melanoma skin cancer programs, the Verrica news page offers a consolidated view of the company’s clinical, regulatory, commercial and financial disclosures over time.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced the first patient was dosed in December 2025 in its global Phase 3 program evaluating YCANTH (VP-102) for common warts.
The Phase 3 start follows positive Phase 2 COVE-1 topline results where 51% (18 of 35) of subjects in Cohort 2 achieved complete clearance at Day 84; adverse events were primarily local cutaneous reactions with no SAEs observed. Verrica retains global rights to YCANTH outside Japan.
Torii will split Phase 3 costs 50/50, funding the first $40 million (about 90% of the current trial budget); Verrica recently completed a $50 million financing and repaid its OrbiMed debt facility. Verrica cites a U.S. prevalence of ~22 million patients and no FDA‑approved therapies for common warts.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced a private placement PIPE financing raising approximately $50 million in gross proceeds, expected to close on or about November 25, 2025. Verrica said it will use about $35.0 million of net proceeds to fully repay its credit agreement with OrbiMed and the remainder for working capital, extending its expected cash runway into mid-2027.
The financing is anchored by Caligan Partners and PBM Capital, includes sales of common stock, pre-funded warrants and accompanying Series C warrants, and gives Caligan the right to designate a board member.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported $14.3M revenue in Q3 2025, driven by $3.6M YCANTH product sales and $10.7M license/collaboration revenue (including a $10M Torii milestone for Japan approval).
The company said dispensed YCANTH applicators rose to 37,642 YTD (a 120% increase vs prior year) and Q3 dispensings were 14,093 (+4.9% sequential). FDA and EMA provided positive regulatory feedback for VP-315 Phase 3 and YCANTH MAA pathways; Torii will fund most global Phase 3 wart trial costs. Q3 net loss was $0.3M and cash totaled $21.1M as of September 30, 2025.
Verrica Pharmaceuticals (Nasdaq: VRCA) presented Phase 2 translational and clinical data for VP-315 at SITC (Nov 5–9, 2025). In Part 2, 82 subjects (92 tumors) received intratumoral VP-315; an exploratory immune analysis in 22 subjects (24 tumors) showed increased CD3+, CD4+, CD8+ T-cell and CD20+ B-cell densities and reduced immunosuppressive cells 12–14 weeks post-treatment.
Clinical outcomes reported: 97% objective response rate (post-hoc), 51% complete histologic clearance, 86% overall tumor-size reduction, and no treatment-related serious adverse events. Company reported End-of-Phase 2 FDA agreement and is preparing a pivotal Phase 3 program.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that the CHMP of the European Medicines Agency provided positive scientific advice supporting a Marketing Authorization Application (MAA) for YCANTH as a treatment for molluscum contagiosum.
The CHMP concluded that the primary and supportive secondary endpoints from previously completed Phase 3 studies in the U.S. and Japan are adequate and no additional Phase 3 studies are required. Verrica is initiating activities to support an MAA submission that could be filed as early as Q4 2026. The feedback covers adult and pediatric patients aged 2 years and older, and addresses study design, clinical safety data, and nonclinical/literature adequacy.
Verrica Pharmaceuticals (Nasdaq: VRCA) will present new Phase 2 data on VP-315, an oncolytic peptide for basal cell carcinoma (BCC), at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, November 5–9, 2025, in National Harbor, Maryland.
The company will deliver an oral presentation (Abstract 529) on November 6, 2025 during Concurrent Session 205b with a 12:46–12:54 p.m. ET presentation slot exploring local immune activation in the tumor microenvironment 12 weeks after VP-315. A companion poster with the same exploratory analysis will also be presented. The abstract will be posted on the SITC website on or about November 4, 2025 at 9:00 a.m. ET.
Verrica Pharmaceuticals (NASDAQ:VRCA) announced that its development partner, Torii Pharmaceutical, has received approval from Japan's Ministry of Health for YCANTH® (TO-208) to treat Molluscum Contagiosum. This approval triggers a $10 million milestone payment to Verrica, strengthening its balance sheet with non-dilutive capital.
The approval follows positive Phase 3 trial results in Japan, where YCANTH demonstrated statistically significant efficacy in achieving complete clearance of molluscum lesions compared to placebo. Verrica maintains global rights to YCANTH outside Japan and plans to initiate a global Phase 3 program for common warts treatment by the end of 2025.
Verrica Pharmaceuticals (NASDAQ:VRCA), a dermatology therapeutics company, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will present on Monday, September 8, 2025, at 9:30 am ET.
Investors can access the presentation through a live webcast available on Verrica's website, with a replay available for 90 days following the event.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported strong Q2 2025 financial results with total revenue of $12.7 million, including $4.5 million from YCANTH® sales and $8.0 million in milestone revenue from Torii Pharmaceutical. YCANTH showed impressive growth with 13,434 dispensed applicator units, representing a 32.8% sequential increase from Q1 2025.
The company achieved a net income of $0.2 million ($0.02 per share) compared to a net loss of $17.2 million in Q2 2024. Verrica completed a successful End of Phase 2 Meeting for VP-315 in basal cell carcinoma and is preparing for Phase 3 while exploring non-dilutive financing options. The company expects an additional $10 million milestone payment upon Japanese regulatory approval of YCANTH by year-end 2025.
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, will host a conference call and webcast on August 12, 2025, at 4:30 p.m. ET to discuss its Q2 2025 financial results and provide a corporate update.
Participants can join via telephone using 1-800-267-6316 (domestic) or 1-203-518-9783 (international) with conference ID: VERRICA. The webcast will be available on the company's investor relations website and archived for 90 days.
FAQ
What is the current stock price of Verrica Pharmaceuticals (VRCA)?
What is the market cap of Verrica Pharmaceuticals (VRCA)?
